david ettinger, md, on the positioning of ramucirumab (cyramza) for nsclc
Published 8 years ago • 343 plays • Length 0:56
Download video MP4
Download video MP3
Similar videos
-
0:59
david gandara, md, discusses the positioning of cyramza post platinum therapy in nsclc patients
-
0:25
david ettinger, md, on choosing between immunotherapy and chemotherapy in metastatic nsclc patients
-
0:35
david ettinger, md, talks about impact of immunotherapy in 1st line metastatic nsclc patients
-
1:01
david r. gandara, md, shares the benefits of using ramucirumab plus docetaxel in 2nd line nsclc
-
0:35
david ettinger, md, on cost of therapy when choosing agents for late stage lung cancer patients
-
1:11
david ettinger, md, provides practical advice related to pd-l1 testing in metastatic nsclc patients
-
0:47
david ettinger, md, talks about levels of pd-l1 expression and agent selection
-
2:09
howard hochster, md, explains the role of ramucirumab in the treatment of ge junction cancers
-
0:46
clinical trials in lung cancer explained video
-
1:08
manish shah, md, on the role of cyramza in the treatment of gastric and esophageal cancers
-
1:12
sam klempner, md, describes the role of cyramza in the treatment of gr junction cancers
-
1:32
david gandara, md, talks about the potential impact of immunotherapy in 1st line nsclc
-
1:34
dr. david gandara on patient selection for molecular testing in lung cancer
-
0:31
david gandara, md, discusses pembrolizumab vs docetaxel for previously treated nsclc patients
-
![[lung] selpercatinib, patient-reported outcomes (2022 feb oncologist)](https://i.ytimg.com/vi/mxADEwEZ2ng/mqdefault.jpg)
3:18
[lung] selpercatinib, patient-reported outcomes (2022 feb oncologist)
-
2:01
sebastian fernandez-bussy, m.d.: interventional pulmonologist
-
0:57
jasgit sachdev, md, discusses the paloma-2 randomized study
-
0:37
why did you choose interventional pulmonology?
-
3:05
david guidry, m.d.
Clip.africa.com - Privacy-policy